Drug Development | SRI International

Toggle Menu

Drug Development

SRI Biosciences provides clients with a wide range of services for moving new drug candidates from the laboratory into clinical testing and to the marketplace. The only full-service contract research organization based on the West Coast, SRI works with large and small pharmaceutical and biotechnology clients, including global pharmaceutical companies and start-up biotechnology ventures.

 

We also serve the nonclinical needs of the National Cancer Institute (NCI), the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Mental Health (NIMH), and the National Institute of Aging (NIA).

 

Scope of Services

To help clients meet their product development objectives, SRI Biosciences offers services ranging from comprehensive drug safety evaluations to scale-up processing of prototype clinical trial materials (CTMs). We provide clients with more than six decades of expertise and facilities equipped with sophisticated scientific instrumentation. We have AAALAC-accredited facilities and a modern functional manufacturing facility, including an aseptic processing suite.

All of SRI's pharmaceutical development services meet worldwide stringent regulatory requirements. SRI studies are conducted under Good Laboratory Practice (GLP) and current Good Manufacturing Practice (cGMP) regulations. For biotech and pharmaceutical clients that need specialized expertise in the discovery phase, SRI provides discovery services for target research initiatives or as an ongoing development resource.

Key development services include

Projects

Innovative Science Overcomes Formulation Challenges

Innovative Science Overcomes Formulation Challenges

Partnering to Advance Therapy for Radiation Exposure

Partnering to Advance Therapy for Radiation Exposure

The Integrin αvβ6 Increases During the Pathogenesis of Squamous Cell Carcinoma of the Lung

Identification of Cell-Specific Biomarkers

SRI’s Brown Laboratory is using selected peptides as “fishing hooks” to identify novel cell surface features.

A peptide that targets dendritic cells delivers quantum dots intracellularly.

Targeted Immunotherapies for Cancer

SRI's Brown Laboratory is taking multiple approaches to develop effective anti-cancer immunotherapies.